603127 昭衍新药
已收盘 09-24 15:00:00
资讯
新帖
简况
昭衍新药（603127）9月23日主力资金净买入1.25亿元
证券之星 · 08:18
昭衍新药（603127）9月23日主力资金净买入1.25亿元
昭衍新药：认购中信证券金融产品 投资金额5.4亿元
南方财经网 · 09-23 16:53
昭衍新药：认购中信证券金融产品 投资金额5.4亿元
CRO概念股早盘多数走高 金斯瑞生物科技及昭衍新药均涨超4%
新浪港股 · 09-23 11:40
CRO概念股早盘多数走高 金斯瑞生物科技及昭衍新药均涨超4%
医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一
金吾财讯 · 09-21
医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一
港股午评|恒生指数早盘涨0.67% AI制药板块大涨
智通财经 · 09-18
港股午评|恒生指数早盘涨0.67% AI制药板块大涨
CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%
金吾财讯 · 09-18
CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%
剂泰科技-P午前涨逾14% 携手昭衍新药打造mRNA药物创新研发与产业化制造平台
新浪港股 · 09-17
剂泰科技-P午前涨逾14% 携手昭衍新药打造mRNA药物创新研发与产业化制造平台
每周股票复盘：昭衍新药（603127）Q3盈利将显著改善
证券之星 · 09-13
每周股票复盘：昭衍新药（603127）Q3盈利将显著改善
股市必读：昭衍新药（603127）9月8日披露最新机构调研信息
证券之星 · 09-09
股市必读：昭衍新药（603127）9月8日披露最新机构调研信息
昭衍新药：9月8日召开业绩说明会，投资者参与
证券之星 · 09-08
昭衍新药：9月8日召开业绩说明会，投资者参与
猴价是否还将上涨？“猴茅”昭衍新药总经理最新回应
滚动播报 · 09-08
猴价是否还将上涨？“猴茅”昭衍新药总经理最新回应
午评：沪指半日涨0.36% 农业板块强势领涨
中金财经 · 09-08
午评：沪指半日涨0.36% 农业板块强势领涨
直击昭衍新药业绩说明会：高管回应净利润大增、主业亏损等问题
大河财立方 · 09-08
直击昭衍新药业绩说明会：高管回应净利润大增、主业亏损等问题
昭衍新药：国内非人灵长类实验动物的供需呈现紧张状态
格隆汇 · 09-08
昭衍新药：国内非人灵长类实验动物的供需呈现紧张状态
每周股票复盘：昭衍新药（603127）H股及A股股本与股份无变动
证券之星 · 09-06
每周股票复盘：昭衍新药（603127）H股及A股股本与股份无变动
昭衍新药（603127）披露8月证券变动月报表，9月2日股价下跌1.28%
证券之星 · 09-02
昭衍新药（603127）披露8月证券变动月报表，9月2日股价下跌1.28%
昭衍新药（603127）2026年中报简析：营收净利润同比双双增长
证券之星 · 08-30
昭衍新药（603127）2026年中报简析：营收净利润同比双双增长
每周股票复盘：昭衍新药（603127）Q2净利同比增2469.84%
证券之星 · 08-30
每周股票复盘：昭衍新药（603127）Q2净利同比增2469.84%
昭衍新药（603127）披露召开2026年半年度业绩说明会公告，8月28日股价下跌1.25%
证券之星 · 08-28
昭衍新药（603127）披露召开2026年半年度业绩说明会公告，8月28日股价下跌1.25%
昭衍新药(06127)公布中期业绩 股东应占溢利约7.48亿元 同比增长约11.27倍
智通财经 · 08-28
昭衍新药(06127)公布中期业绩 股东应占溢利约7.48亿元 同比增长约11.27倍
加载更多
公司概况
公司名称：
北京昭衍新药研究中心股份有限公司
所属行业：
研究和试验发展
上市日期：
2017-08-25
主营业务：
北京昭衍新药研究中心股份有限公司的主营业务是提供药物非临床研究服务。公司的主要产品是非临床评价服务和药物发现服务、临床试验全流程服务、专业临床检测服务、实验模型研究。
发行价格：
12.51
{"stockData":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":46.39,"timestamp":1790233200000,"preClose":47.77,"halted":0,"volume":41845354,"delay":0,"changeRate":-0.0289,"floatShares":628000000,"shares":749000000,"eps":1.3138,"marketStatus":"已收盘","change":-1.38,"latestTime":"09-24 15:00:00","open":48.95,"high":49.72,"low":46.34,"amount":2002000000,"amplitude":0.0708,"askPrice":46.4,"askSize":174,"bidPrice":46.39,"bidSize":245,"shortable":0,"etf":0,"ttmEps":1.3138,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":5,"adr":0,"adjPreClose":47.77,"symbolType":"stock","openAndCloseTimeList":[[1790213400000,1790220600000],[1790226000000,1790233200000]],"highLimit":52.55,"lowLimit":42.99,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":749348220,"isCdr":false,"pbRate":3.99,"roa":"--","peRate":35.309788,"roe":"8.61%","epsLYR":0.4,"committee":0.635202,"marketValue":34762000000,"turnoverRate":0.0667,"status":1,"hkstockBrief":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":27.14,"timestamp":1790233604054,"preClose":27.56,"halted":0,"volume":5600249,"delay":0,"premium":"-49.92"},"floatMarketCap":29120000000},"requestUrl":"/m/hq/s/603127","defaultTab":"news","newsList":[{"id":"2669322324","title":"昭衍新药（603127）9月23日主力资金净买入1.25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669322324","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669322324?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:18","pubTimestamp":1790209123,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，昭衍新药报收于47.77元，上涨3.58%，换手率7.96%，成交量49.96万手，成交额23.98亿元。9月23日的资金流向数据方面，主力资金净流入1.25亿元，占总成交额5.22%，游资资金净流出5953.8万元，占总成交额2.48%，散户资金净流出6569.04万元，占总成交额2.74%。融券方面，融券卖出4.1万股，融券偿还100.0股，融券余量26.03万股，融券余额1243.45万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400007716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","603127","BK1576","BK1141","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669910137","title":"昭衍新药：认购中信证券金融产品 投资金额5.4亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669910137","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669910137?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:53","pubTimestamp":1790153580,"startTime":"0","endTime":"0","summary":"南财智讯9月23日电，昭衍新药（06127.HK）发布须予披露交易公告，于2026年4月20日至2026年9月23日期间，公司附属公司透过中信证券及其附属公司认购了七项中信证券金融产品，合计投资金额为人民币5.4亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609233882481581.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609233882481581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","LU1997244956.HKD","LU1794554557.SGD","06127","BK0188","BK1576","BK1564","BK0196","LU2495084118.USD","BK1141","LU1328615791.USD","LU2580892789.USD","LU1781817850.SGD","LU0405327494.USD","BK0012","LU1580142542.USD","LU1655091616.SGD","06030","BK0028","159940","LU1997245177.USD","600030","LU0405327148.USD","LU1146622755.USD","BK1521","LU2148510915.USD","LU2289578879.USD","BK0216","LU1720050803.USD","BK1516","LU1064131003.USD","LU1820825898.SGD","LU1255011170.USD","BK0183","BK0276","BK1147","603127","LU1997245094.SGD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669174258","title":"CRO概念股早盘多数走高 金斯瑞生物科技及昭衍新药均涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669174258","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669174258?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:40","pubTimestamp":1790134800,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端CRO概念股早盘多数走高，截至发稿，金斯瑞生物科技（01548）上涨4.70%，报42.36港元；昭衍新药（06127）上涨4.45%，报27.70港元；康龙化成（03759）上涨2.51%，报31.02港元；泰格医药（03347）上涨0.82%，报46.96港元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-23/doc-inisusyi5326555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603127","HK0000320264.USD","HK0000320223.HKD","BK0216","HK0000306685.HKD","HK0000306701.USD","06127","01548","BK1583","BK1141","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139506","title":"医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139506","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139506?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:10","pubTimestamp":1789956632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初走高，截至发稿，昭衍新药（06127）涨6.14%，药明生物（02269）涨4.97%，金斯瑞生物科技（01548）涨4.47%，维亚生物（01873）涨3.75%，药明康德（02359）涨3.40%，泰格医药（03347）涨2.52%，康龙化成（03759）涨2.64%。中邮证券研究指，2026中报看，CXO行业是医药行业中最亮眼板块之一。数据上看，CDMO龙头、安评及临床CRO是三条景气主线。估值上看，CDMO龙头公司按2027PE仍处于合理区间，CRO环节公司报表仍处修复阶段，新签高毛利订单待转化，因此表观估值较高，但预计随着订单的逐渐周转快速消化。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0181495838.USD","LU0348766576.USD","BK1161","03347","LU1880383366.USD","LU3063872942.SGD","LU0561508036.HKD","603127","HK0000306701.USD","LU0029874905.USD","LU0359202008.SGD","BK1141","LU0540923850.HKD","LU1242518857.USD","BK1583","LU1794554557.SGD","LU0043850808.USD","LU0516422440.USD","LU0516422366.SGD","BK1515","LU0588546209.SGD","02359","LU0516422952.EUR","01548","LU0348825331.USD","LU0051755006.USD","BK1589","09939","03759","HK0000320223.HKD","06127","LU0307460666.USD","LU2242644610.SGD","CXO","159938","LU2125910500.SGD","SG9999002463.SGD","01873","LU0516423091.SGD","KURE","02269","LU0359201612.USD","LU0456846285.SGD","LU0052750758.USD","LU0516423174.USD","WX","LU0039217434.USD","BK1610","LU0029874061.USD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668191239","title":"港股午评|恒生指数早盘涨0.67% AI制药板块大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2668191239","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668191239?lang=zh_cn&edition=full","pubTime":"2026-09-18 12:00","pubTimestamp":1789704004,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.67%，涨164点，报24768点；恒生科技指数涨1.74%。港股早盘成交1070亿港元。十部门印发医药十五五规划，机构看好医药迎“Claude”时刻。AI制药进入战略入局阶段。曦智科技-P涨超17%。天数智芯涨超13%，公司有望持续受益AI资本开支的增长及算力自主可控浪潮。MINIMAX-W涨13%，旗下多款产品通过Singtel AI Pass纳入配套订阅计划。俊知集团涨超10%，收购青海中利光纤技术有望打开AI算力相关光纤产品增量空间。大股东解禁期满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0264606111.USD","603127","LU0972618739.USD","LU0862451837.USD","07666","LU1366334651.USD","03033","BK1544","513600","BK1592","LU1831875114.USD","02228","BK1161","BK1506","07552","09067","LU0463099449.HKD","LU0791591158.USD","02833","07200","00992","HK0000320223.HKD","BK1526","HSTECH","LU2242644610.SGD","IE0003895053.USD","07300","03423","BK1149","LU0791590937.USD","HK0000320264.USD","01879","09088","LU1366334578.USD","06658","83115","IE00B0JY6N72.USD","LU0862451753.SGD","LU1808992512.USD","LU0244354667.USD","LU0048580855.USD","LU0181495838.USD","07500","03067","BK1193","LNVGY","LU0320764755.SGD","LU0672654166.SGD","09903","LU0828237940.HKD","03032","BK1574","00100","02837","BK1117","LU0348825331.USD","03115","LU0417516902.SGD","LU0052756011.USD","LU0348827113.USD","LU1267930227.SGD","02701","BK1141","BK1583","03088","HK0000306701.USD","BK1183","BK1237","LU0890818403.SGD","LU0543330483.HKD","BK1617","80992","LU0310800965.SGD","BK1163","IE0034224299.USD","BK1198","LU0049112450.USD","01300","82800","BK1576","LU0128525689.USD","01818","IE0032431581.USD","09115","LU0140636845.USD","LU0572940350.SGD","HHImain","03696","BK1607","TCHI","LU1785774172.SGD","03419","LU0572939691.SGD","07630","03037","LU1046422090.SGD","02800","LU1235295612.USD","LU0128522157.USD","LU0326950275.SGD","07226","HSI","LU0561508036.HKD","600547","01787","02656","02670","HK0000306685.HKD","06127","LU0029875118.USD","300077","LU1188198961.HKD","02142","MCHmain","LU0370786039.SGD","BK1197","03417"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919819","title":"CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919819","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919819?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:46","pubTimestamp":1789695974,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块上扬，昭衍新药 涨5.64%，金斯瑞生物科技涨4.78%，维亚生物涨2.15%，泰格医药涨1.93%，药明生物涨1.80%，凯莱英涨1.79%，药明康德涨1.01%，百济神州涨0.95%。中信建投近日研报指，CXO是创新药产业链专业化分工的重要载体，也是连接药物研发与商业化生产的关键基础设施。随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991930","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6N72.USD","LU0456846285.SGD","LU0051755006.USD","LU0828237510.HKD","01548","LU0039217434.USD","LU0181495838.USD","LU0588546209.SGD","KURE","LU0561508036.HKD","02359","LU0634319403.HKD","06127","LU0228659784.USD","LU3063872942.SGD","LU1251922891.USD","LU1880383366.USD","LU0856984785.SGD","LU1719994722.HKD","LU2039709279.SGD","WX","LU1242518857.USD","06821","LU0320764243.SGD","LU0359202008.SGD","BK0216","01873","LU0320764599.SGD","SG9999002562.SGD","03347","LU0348735423.USD","LU1242518931.SGD","02269","LU1688375341.USD","603127","CXO","LU0052750758.USD","LU0348827113.USD","BK1161","BK1521","LU0029874905.USD","LU2242644610.SGD","06160","BK1588","LU0348825331.USD","LU0469268626.HKD","BK1610","LU0029874061.USD","LU0516423174.USD","LU0128522744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668580019","title":"剂泰科技-P午前涨逾14% 携手昭衍新药打造mRNA药物创新研发与产业化制造平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2668580019","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668580019?lang=zh_cn&edition=full","pubTime":"2026-09-17 11:28","pubTimestamp":1789615680,"startTime":"0","endTime":"0","summary":"模拟交易客户端剂泰科技-P盘中涨超16%，截至发稿，股价上涨13.79%，现报15.68港元，成交额1.53亿港元。近日，据剂泰科技官微消息，公司与昭衍生物正式签署合资协议，共同设立合资公司昭泰智药，携手打造mRNA药物创新研发与产业化制造平台。根据协议，剂泰科技将在上游提供设计与递送能力，NanoForge已实现对人体内8个关键器官与组织的靶向递送。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-17/doc-inisayan9411675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603127","BK1141","BK1161","BK0216","BK1576","07666","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667050229","title":"每周股票复盘：昭衍新药（603127）Q3盈利将显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2667050229","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667050229?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:15","pubTimestamp":1789233312,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，昭衍新药报收于41.37元，较上周的42.94元下跌3.66%。本周，昭衍新药9月9日盘中最高价报44.08元。三季度稳步改善，四季度因高价订单集中结转，营收与利润率将显著提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","BK1141","BK0216","603127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374812","title":"股市必读：昭衍新药（603127）9月8日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666374812?lang=zh_cn&edition=full","pubTime":"2026-09-09 00:26","pubTimestamp":1788884780,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，昭衍新药报收于43.62元，上涨1.87%，换手率5.74%，成交量36.06万手，成交额15.58亿元。交易信息汇总资金流向9月8日主力资金净流入7016.98万元，占总成交额4.5%；游资资金净流入1.28亿元，占总成交额8.24%；散户资金净流出1.99亿元，占总成交额12.75%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900001285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","06127","BK0216","BK1576","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665379322","title":"昭衍新药：9月8日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2665379322","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665379322?lang=zh_cn&edition=full","pubTime":"2026-09-08 23:01","pubTimestamp":1788879699,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月8日昭衍新药发布公告称公司于2026年9月8日召开业绩说明会。昭衍新药2026年中报显示，上半年度公司主营收入7.04亿元，同比上升5.27%；归母净利润7.48亿元，同比上升1126.8%；扣非净利润6.99亿元，同比上升2931.69%；其中2026年第二季度，公司单季度主营收入3.88亿元，同比上升1.69%；单季度归母净利润5.09亿元，同比上升2469.84%；单季度扣非净利润4.81亿元，同比上升18544.78%；负债率17.09%，投资收益558.44万元，财务费用-2360.59万元，毛利率23.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800038211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","06127","BK1576","603127","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378399","title":"猴价是否还将上涨？“猴茅”昭衍新药总经理最新回应","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378399","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665378399?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:40","pubTimestamp":1788867600,"startTime":"0","endTime":"0","summary":"对此，昭衍新药董事、总经理兼董事会秘书高大鹏在9月8日的2026年半年度业绩说明会上给予了回应。2026年上半年，昭衍新药营业收入为7.04亿元，同比仅增长5.27%；净利润为7.48亿元，同比增长1126.8%。在对实验猴价格有较大影响的进口政策和供给约束方面，高大鹏回应称，目前进口政策已放开，种猴和商品猴均可进口，从实际情况看，今年非人灵长类进口以商品猴为主。9月8日，昭衍新药股价以43.62元/股报收，最新市值为298亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-08/doc-inircmeq9296831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1576","603127","BK0216","BK1141","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342360","title":"午评：沪指半日涨0.36% 农业板块强势领涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342360","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665342360?lang=zh_cn&edition=full","pubTime":"2026-09-08 13:22","pubTimestamp":1788844922,"startTime":"0","endTime":"0","summary":" 9月8日，三大指数涨跌不一，沪指表现较强。 板块方面，农业板块反复活跃，亚盛集团4连板，苏垦农发、敦煌种业、中粮科技、华康股份涨停；文化传媒板块拉升，中信出版、龙版传媒、新华都、中国出版涨停；金属铜板块震荡走强，精艺股份涨停；房地产板块集体上涨，深物业A、盈新发展、我爱我家涨停。 截至午间收盘，沪指涨0.36%，深证成指涨0.05%，创业板指跌0.15%，科创50指数跌0.42%。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/08/20260908334215.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/08/20260908334215.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260908/32363122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002295","BK0012","516550","000011","BK0216","BK0229","BK0127","03147","BK0164","000001","BK0199","BK0105","600354","LU1781817850.SGD","603127","BK0092","LU1993786604.SGD","BK0157","BK0278","BK0248","LU0067412154.USD","601952","605077","BK0187","000930","BK0104","BK0233","600108","BK0173","BK0238","LU1226287529.USD","000560","BK0183","LU1580142542.USD","BK0188","399006","BK0227","BK0077","BK0273","LU0880133367.SGD","BK0007","06127","BK0201","LU1655091616.SGD","BK0010","BK0186","LU0501845795.SGD","IE00B0JY6N72.USD","07234","BK0190","BK0028","BK0082","LU0072913022.USD","BK0102","LU1807302812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665344534","title":"直击昭衍新药业绩说明会：高管回应净利润大增、主业亏损等问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2665344534","media":"大河财立方","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665344534?lang=zh_cn&edition=full","pubTime":"2026-09-08 12:02","pubTimestamp":1788840164,"startTime":"0","endTime":"0","summary":"【大河财立方记者吴春波】9月8日，昭衍新药（603127.SH/06127.HK）通过上证路演中心召开2026年半年度业绩说明会。公司董事、总经理兼董事会秘书高大鹏，就投资者关心的净利润大增、主营业务亏损、订单增长及实验猴价格走势等问题进行了集中回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083867884147.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083867884147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06127","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349147","title":"昭衍新药：国内非人灵长类实验动物的供需呈现紧张状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349147","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665349147?lang=zh_cn&edition=full","pubTime":"2026-09-08 10:44","pubTimestamp":1788835466,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0216","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665365855","title":"每周股票复盘：昭衍新药（603127）H股及A股股本与股份无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2665365855","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665365855?lang=zh_cn&edition=full","pubTime":"2026-09-06 01:10","pubTimestamp":1788628220,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，昭衍新药报收于42.94元，较上周的47.54元下跌9.68%。公司公告汇总H股公告：8月月报表北京昭衍新药研究中心股份有限公司提交截至2026年8月31日的证券变动月报表，显示公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股总数为118,995,206股，于香港联交所上市；A股总数为630,353,014股，其中已发行股份629,815,394股，库存股537,620股，未在港交所上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","03188","02827","83130","BK1576","159982","BK1147","07233","03130","82846","02846","603127","83188","399300","BK1141","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664681762","title":"昭衍新药（603127）披露8月证券变动月报表，9月2日股价下跌1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664681762","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664681762?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:10","pubTimestamp":1788358228,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，昭衍新药报收于44.6元，较前一交易日下跌1.28%，最新总市值为334.21亿元。该股当日开盘45.18元，最高45.66元，最低44.03元，成交额达12.86亿元，换手率为4.58%。近日，公司发布H股公告《8月月报表》。公司确认2026年8月无股份增减，公众持股量符合上市规则要求，且所有证券发行事项均已获董事会批准并遵守相关法规。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200042690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","06127","603127","BK0216","161027","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048925","title":"昭衍新药（603127）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048925?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:11","pubTimestamp":1788041472,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期昭衍新药发布2026年中报。根据财报显示，昭衍新药营收净利润同比双双增长。截至本报告期末，公司营业总收入7.04亿元，同比上升5.27%，归母净利润7.48亿元，同比上升1126.8%。本文数据来源于昭衍新药2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010890","title":"每周股票复盘：昭衍新药（603127）Q2净利同比增2469.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010890","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010890?lang=zh_cn&edition=full","pubTime":"2026-08-30 01:26","pubTimestamp":1788024370,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，昭衍新药报收于47.54元，较上周的49.27元下跌3.51%。本周关注点业绩披露要点：2026年第二季度归母净利润5.09亿元，同比上升2469.84%。业绩披露要点昭衍新药2026年中报显示，上半年度公司主营收入7.04亿元，同比上升5.27%；归母净利润7.48亿元，同比上升1126.8%；扣非净利润6.99亿元，同比上升2931.69%。第二季度单季度主营收入3.88亿元，同比上升1.69%；单季度归母净利润5.09亿元，同比上升2469.84%；单季度扣非净利润4.81亿元，同比上升18544.78%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000000512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK0216","06127","603127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662833099","title":"昭衍新药（603127）披露召开2026年半年度业绩说明会公告，8月28日股价下跌1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662833099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662833099?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:02","pubTimestamp":1787925731,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，昭衍新药报收于47.54元，较前一交易日下跌1.25%，最新总市值为356.24亿元。该股当日开盘48.0元，最高51.51元，最低47.5元，成交额达18亿元，换手率为5.88%。公司将于2026年9月8日9:00-10:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司半年度经营成果及财务状况。投资者可于2026年9月1日至9月7日16:00前通过上证路演中心网站或公司邮箱提交问题。说明会结束后可通过该平台查看会议内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800053403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","603127","BK1141","BK0216","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662066223","title":"昭衍新药(06127)公布中期业绩 股东应占溢利约7.48亿元 同比增长约11.27倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2662066223","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662066223?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:54","pubTimestamp":1787910886,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昭衍新药(06127)公布2026年中期业绩，收益约7.04亿元，同比增长5.3%;公司权益股东应占期内溢利约7.48亿元，同比增长约11.27倍;每股盈利1元。报告期内，公司整体在手订单金额约为37亿元，同比增长60.9%;新签订单金额约为20.2亿元，同比增长98.0%。公告称，净利润增加主要是由于生物资产公平值变动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BK1141","06127","BK1576","603127"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790233617769,"stockEarnings":[{"period":"1week","weight":0.0899},{"period":"1month","weight":0.0297},{"period":"3month","weight":0.2409},{"period":"6month","weight":0.5844},{"period":"1year","weight":0.3116},{"period":"ytd","weight":0.3686}],"compareEarnings":[{"period":"1week","weight":0.0115},{"period":"1month","weight":0.014},{"period":"3month","weight":-0.0446},{"period":"6month","weight":0.0058},{"period":"1year","weight":0.03},{"period":"ytd","weight":-0.0081}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京昭衍新药研究中心股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2017-08-25","address":"北京市大兴区北京经济技术开发区荣京东街甲5号","registeredCapital":"74934万元","survey":" 北京昭衍新药研究中心股份有限公司的主营业务是提供药物非临床研究服务。公司的主要产品是非临床评价服务和药物发现服务、临床试验全流程服务、专业临床检测服务、实验模型研究。","listedPrice":12.51},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,603127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}